



## Coherus BioSciences to Report Third Quarter 2018 Financial Results on November 8th

Oct 22, 2018

REDWOOD CITY, Calif., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS) today announced that its third quarter 2018 financial results will be released after market close on Thursday, November 8, 2018. Starting at 4:30 p.m. ET, Coherus' management will host a conference call to discuss the financial results and provide a general business update.

After releasing third quarter 2018 financial results, we will post them on the Coherus website at <http://investors.coherus.com>.

### Conference Call Information

When: Thursday, November 8, 2018 at 4:30 p.m. ET

Dial-in: (844) 452-6826 (toll free) or (765) 507-2587 (International)

Conference ID: 7181479

Webcast: <http://investors.coherus.com>

Please join the conference call at least 10 minutes early to register. The webcast will be archived on the Coherus website.

### About Coherus BioSciences, Inc.

Coherus is a leading biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales & marketing and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, UDENYCA™ (pegfilgrastim-cbqv), CHS-1420 (adalimumab biosimilar) and CHS-0214 (etanercept biosimilar), as well as developing a robust pipeline of future products in ophthalmology (including CHS-3351, a ranibizumab biosimilar, and CHS-2020, an aflibercept biosimilar), and CHS-131, a small molecule for nonalcoholic steatohepatitis (NASH) and multiple sclerosis. For additional information, please visit [www.coherus.com](http://www.coherus.com).

### CONTACT:

David S. Arrington

VP, Corporate Communications and Public Affairs, Investor Relations

Coherus BioSciences, Inc.

[darrington@coherus.com](mailto:darrington@coherus.com)

+1 (650) 395-0196



Source: Coherus BioSciences, Inc.